Why the study?
What are the clinical practice preferences for oral anticoagulation therapy in patients with atrial fibrillation across European centres?
What are the clinical practice preferences for oral anticoagulation therapy in patients with atrial fibrillation across European centres?
This survey highlights that while NOACs are widely accepted for general stroke prophylaxis in AF, there is significant practice variation and lower preference for NOACs in complex scenarios like post-PCI triple therapy.
No takes yet. Share an insight, caveat, or question.
Practice variation in AF-PCI anticoagulation persists across Europe; leaves open optimal regimens for prospective trials.
Larsen et al. (2015) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: